SBTX vs. CVAC, ABVX, TYRA, CNTA, PRTC, EOLS, PRAX, AUPH, NRIX, and ETNB
Should you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include CureVac (CVAC), ABIVAX Société Anonyme (ABVX), Tyra Biosciences (TYRA), Centessa Pharmaceuticals (CNTA), PureTech Health (PRTC), Evolus (EOLS), Praxis Precision Medicines (PRAX), Aurinia Pharmaceuticals (AUPH), Nurix Therapeutics (NRIX), and 89bio (ETNB). These companies are all part of the "pharmaceutical preparations" industry.
Silverback Therapeutics (NASDAQ:SBTX) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.
Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, CureVac has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500.
In the previous week, CureVac had 3 more articles in the media than Silverback Therapeutics. MarketBeat recorded 4 mentions for CureVac and 1 mentions for Silverback Therapeutics. CureVac's average media sentiment score of 0.38 beat Silverback Therapeutics' score of 0.00 indicating that CureVac is being referred to more favorably in the news media.
Silverback Therapeutics has a net margin of 0.00% compared to CureVac's net margin of -463.49%. Silverback Therapeutics' return on equity of -29.62% beat CureVac's return on equity.
CureVac received 4 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. However, 56.25% of users gave Silverback Therapeutics an outperform vote while only 51.16% of users gave CureVac an outperform vote.
74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Silverback Therapeutics has higher earnings, but lower revenue than CureVac. Silverback Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
CureVac has a consensus price target of $8.33, suggesting a potential upside of 114.22%. Given CureVac's higher probable upside, analysts plainly believe CureVac is more favorable than Silverback Therapeutics.
Summary
CureVac beats Silverback Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Silverback Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silverback Therapeutics Competitors List
Related Companies and Tools
